BioLine Rx Ltd (BLRX) Full Year 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
BioLineRx Ltd. - American Depositary Shares (BLRX)
Last biolinerx ltd. - american depositary shares earnings: 5/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.biolinerx.com
Company Research
Source: Yahoo! Finance
Research and Development Expenses: $8.1 million for 2025, down from $9.2 million in 2024. General and Administrative Expenses: $3.1 million for 2025, compared to $6.3 million in 2024. Net Loss: $2 million for 2025, compared to $9.2 million in 2024. Cash and Equivalents: $20.9 million as of December 31, 2025. APHEXDA Sales: $6.5 million in 2025, resulting in $1.2 million of royalty revenue to BioLineRx. Warning! GuruFocus has detected 4 Warning Signs with BLRX. Is BLRX fairly valued? Test your thesis with our free DCF calculator. Release Date: March 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points BioLine Rx Ltd ( NASDAQ:BLRX ) is advancing GLIX1, a first-in-class oral small molecule for glioblastoma, with FDA and EMA Orphan Drug Designation. The company has a strong cash position with $21 million, sufficient to fund operations into the first half of 2027. GLIX1 has shown promising prec
Show less
Read more
Impact Snapshot
Event Time:
BLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLRX alerts
High impacting BioLineRx Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLRX
News
- BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)PR Newswire
- BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- BioLineRx GAAP EPS of $0.00 beats by $0.68, revenue of $1.18M misses by $0.3M [Seeking Alpha]Seeking Alpha
- BioLineRx Reports 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- BioLineRx Reports 2025 Financial Results and Provides Corporate UpdatePR Newswire
BLRX
Sec Filings
- 3/26/26 - Form 6-K
- 3/23/26 - Form 6-K
- 3/23/26 - Form 20-F
- BLRX's page on the SEC website